Skip to content
Screener

Alumis Inc. ALMS Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$3.51B+32.3%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$36.43M-45.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$31.52M-63.2%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$40.46M+191%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$57.25M+24.5%

Segments

By segment

See full
Single Reportable-$98.41M+3.1%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
(in thousands, except share and per share amounts)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Research and development expenses, including related party expenses of $66 and $262 for the three months ended March 31, 2026 and 2025, respectively81,54096,622
General and administrative expenses18,61022,295
Total operating expenses100,150118,917
Loss from operations(98,409)(101,528)
Other income (expense):
Interest income5,3492,609
Other income (expenses), net7(44)
Total other income (expense), net5,3562,565

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s operating income?
Alumis Inc. (ALMS) reported operating income of -$98.41M in Q1 2026.
How has Alumis Inc.'s operating income changed year-over-year?
Alumis Inc.'s operating income increased by 3.1% year-over-year, from -$101.53M to -$98.41M.
What is the long-term trend for Alumis Inc.'s operating income?
Over 2 years (2023 to 2025), Alumis Inc.'s operating income has grown at a 69.4% compound annual growth rate (CAGR), from -$158.17M to -$453.8M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Alumis Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude